Table 1.

Current CPIC guidelines and associated PharmGKB clinical annotation levels and FDA label information

Genea,b	Drug	PharmGKB clinical associationsc	Pharmacogenetics on FDA Labeld	CPIC guideline reference
CFTR	ivacaftor	1A	Genetic testing required	46
CYP2C19	amitriptyline	1A		27
CYP2C19	clopidogrel	1A	Genetic testing recommended	30
CYP2C19	doxepin	3	Actionable pharmacogenetics	27
CYP2C19	imipramine	2A		27
CYP2C19	trimipramine	2A		27
CYP2C19	voriconazole	2A	Actionable pharmacogenetics	In progress
CYP2C19	citalopram	1A	Actionable pharmacogenetics	38
CYP2C19	escitalopram	1A		38
CYP2C9	phenytoin	1B		31
CYP2C9	warfarin	1A	Actionable pharmacogenetics	21
CYP2D6	amitriptyline	1A	Actionable pharmacogenetics	27
CYP2D6	codeine	1A	Actionable pharmacogenetics	23
CYP2D6	desipramine	1A	Actionable pharmacogenetics	27
CYP2D6	doxepin	1A	Actionable pharmacogenetics	27
CYP2D6	fluvoxamine	1A	Informative pharmacogenetics	38
CYP2D6	imipramine	1A	Actionable pharmacogenetics	27
CYP2D6	nortriptyline	1A	Actionable pharmacogenetics	27
CYP2D6	paroxetine	1A	Informative pharmacogenetics	38
CYP2D6	tamoxifen	2A		In progress
CYP2D6	tramadol	1B	Actionable pharmacogenetics	34
CYP2D6	trimipramine	1A	Actionable pharmacogenetics	27
CYP3A5	tacrolimus	1A		39
DPYD	capecitabine	1A	Actionable pharmacogenetics	25
DPYD	fluorouracil	1A	Actionable pharmacogenetics	25
DPYD	tegafur	1A		25
G6PD	rasburicase	1A	Genetic testing required	20
HLA-B	abacavir	1A	Genetic testing required	18, 47
HLA-B	allopurinol	1A		16, 26
HLA-B	carbamazepine	1A	Genetic testing required	28
HLA-B	phenytoin	1A	Actionable pharmacogenetics	31
IFNL3	peg interferon alfa-2b	1A	Actionable pharmacogenetics	36
SLCO1B1	simvastatin	1A		24
TPMT	azathioprine	1A	Genetic testing recommended	19
TPMT	mercaptopurine	1A	Genetic testing recommended	19
TPMT	thioguanine	1A	Actionable pharmacogenetics	19
UGT1A1	atazanavir	1A		37
UGT1A1	irinotecan	2A	Actionable pharmacogenetics	planned
VKORC1	warfarin	1A	Actionable pharmacogenetics	21

^aAssigning CPIC levels to genes and drugs and grouping together genes and drugs for planned CPIC guidelines is a dynamic process that is continually updated. CPIC levels are ultimately decided by the guideline writing committees, who may modify dosing recommendations only after a detailed review of the evidence for genes and drugs. This list was current as of November 2015. The list posted on PharmGKB is the most current list http://www.pharmgkb.org/cpic/pairs.

^bCFTR = cystic fibrosis transmembrane conductance regulator; CYP2C19 = cytochrome P450 family 2 subfamily C member 19; CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2D6 = cytochrome P450 family 2 subfamily D member 6; CYP3A5 = cytochrome P450 family 3 subfamily A member 5; DPYD = dihydropyrimidine dehydrogenase; G6PD = glucose-6-phosphate dehydrogenase; HLA-B = major histocompatibility complex, class I, B; IFNL3 = interferon, lambda 3; SLCO1B1 = solute carrier organic anion transporter family member 1B1; TPMT = thiopurine S-methyltransferase; UGT1A1 = UDP glucuronosyltransferase family 1 member A1; VKORC1 = vitamin K epoxide reductase complex subunit 1

^cPharmGKB Clinical Annotation Levels of Evidence as defined at https://www.pharmgkb.org/page/clinAnnLevels.

^dFDA Label categories created and assigned by PharmGKB, defined at https://www.pharmgkb.org/page/drugLabelLegend#PGxLevel.